Thursday, May 25, 2017

Comparison of access-hole filling materials for screw retained implant prostheses: 12-month in vivo study

International Journal of Implant Dentistry20173:19
DOI: 10.1186/s40729-017-0076-4
Received: 14 December 2016
Accepted: 22 April 2017
Published: 5 May 2017



Screw retained implant prostheses seem to be an efficient restorative method to prevent peri-implantitis caused by cement excess around the abutment. The drawback of the screw-retained prostheses is the difficulty to realize an efficient access-hole filling functionally and aesthetically. Up to now, few in vitro and in vivo studies were reported in the literature. The aim of this study was to evaluate clinical performances of two direct filling materials through a period of 12 months.


To pursue a previous in vitro evaluation, this in vivo 12 months prospective study followed up and compared the access-hole filling integrity of a modified 4-META (4-methacryloxyethyl trimellitate anhydride)/MMA-TBB (methyl methacrylate-tri-n-butyl borane) – based resin (M4M) and a photo-polymerizing nano-hybrid composite resin (CR).
Twenty-eight access-holes were filled with both materials respectively, then impressions and intra-oral photographs were taken at T = 0, T = 1 M (month), 3, 6, and 12 M. The access-hole surface measurement and the margin analysis (depth and angle) were carried out. The VAS (visual analogue scale) value on marginal discoloration and integrity at the baseline T = 0 and T = 12 M was recorded.


The mean values of the surface areas changes from T = 1 to T = 12 M were 83.3 ± 11.5% for group CR and 77.1 ± 13.1% for group M4M, respectively. (Mann-Whitney test p < 0.05, p = 0.046). The mean marginal depth at T = 12 M for group CR were 141.2 ± 125.5 μm and 132.1 ± 107.8 μm for the group M4M, respectively. (Mann-Whitney test p > 0.05, p = 0.58). The mean values of the angle formed at the margin (T = 12 M) were for group CR 39.5 ± 19.4° and 28.2 ± 17.2° for group M4M, respectively (Mann-Whitney test p < 0.0001). The photographical analysis by VAS values showed no significant difference between CR and M4M groups (Mann-Whitney test p > 0.05, p = 0.848).


Based on intra- and extra-oral evaluations with the limitation, both CR and M4M combined with a ceramic primer are indicated as promising materials to fill the access-hole. Further long-term investigation is necessary to confirm this finding.

Wednesday, May 24, 2017

OraCoat® XyliGel® Assists Brace Wearers in Maintaining Good Oral Hygiene

Non-Acidic Soothing Gel Reduces New Plaque Buildup in Patients with Braces

Bellevue, WA (May 23, 2017) – OraCoat® XyliGel® helps reduce plaque and new cavities in brace wearers experiencing food and plaque buildup. The soothing gel acts as a buffer to neutralize harmful acids and works synergistically with a regular cleaning regimen to help preserve good oral hygiene while a patient wears braces.

Brace patients often face the development of tooth decay as a result of food and plaque forming between their brackets and wires. Although brushing and flossing are recommended to combat this issue, food particles may continue to linger, increasing the likelihood of new cavities.
By applying XyliGel between the brackets daily, brace wearers can help prevent new cavities. XyliGel helps to neutralize acids in the mouth with a pH of 7.4 and coats the mouth with xylitol to reduce new plaque formation. “For brace wearers, XyliGel is the perfect complement to regular cleaning,” stated Jeff Haley, OraHealth Corporation Founder, President, and Chief Scientist. “Consistent brushing and flossing after meals can eliminate some buildup; however, regular application of XyliGel greatly aids brace wearers in maintaining good oral hygiene.”

Effective for both daytime and nighttime use, XyliGel increases saliva production and coats the mouth and lips to help relieve dry mouth and reduce new plaque formation. The gel reduces plaque and acidity in the mouth.* XyliGel is the newest member of the OraCoat brand family of products which includes its flagship product, XyliMelts® oral adhering discs for dry mouth.

To order or obtain samples of XyliGel and for additional information on other OraCoat products, please visit

*Documentation of these statements available upon request.

About OraCoat division of OraHealth Corporation
OraCoat®, a division of OraHealth Corporation, is the world leader in the breakthrough technology of “oral adhering discs” which slowly release ingredients in the mouth and are safe for use while sleeping. The OraCoat brand represents a family of products that solve oral care problems by coating the mouth with safe ingredients that become effective when they are slowly released. Our flagship product is XyliMelts® for dry mouth. XyliGel is a companion gel product for reducing plaque in very dry mouths. H-B12 Melts® discs help heal mouth sores. Other oral care solutions in the OraCoat family are planned. OraCoat’s innovative oral care solutions are backed by careful research based on medical science to ensure optimum performance and user safety.

# # #

Tuesday, May 23, 2017

Tooth discoloration effects of calcium silicate based barrier materials used in revascularization and treatment with internal bleaching



Usage of barrier materials is an important step in revascularization procedure. One of the undesired properties of these barrier materials is to cause coronal tooth discoloration. The aim of this in vitro study was to evaluate the tooth discoloration induced by ProRoot MTA (PMTA), Biodentine, and MM-MTA, as well as the efficacy of internal bleaching on this discoloration.

Materials and methods

Forty-two maxillary incisor teeth were prepared. Triple antibiotic paste (TAP) was placed in the root canals and incubated for 3 weeks. After removing the TAP, blood embedded spongostans were inserted into the root canals, and PMTA, Biodentine, or MM-MTA was placed over them. The teeth were incubated for 4 weeks at 37 °C; then, the internal bleaching agent was sealed for one week. The tooth color was measured throughout the study and the color change values (ΔE) of each specimen were calculated, and the data was statistically analyzed using the one-way ANOVA and Tamhane's T2 tests.


The TAP significantly decreased the luminosity of the teeth (p < 0.05); however, no significant differences were observed between the tooth discolorations induced by the PMTA, Biodentine, and MM-MTA (p > 0.05). The teeth in the Biodentine group were more whitened than those of the PMTA and MM-MTA groups (p < 0.05).


Although the PMTA, Biodentine, and MM-MTA caused similar color alterations in the teeth, more bleaching was observed on those teeth discolored using TAP + blood + Biodentine.

Monday, May 22, 2017

Influence of cement type and ceramic primer on retention of polymer-infiltrated ceramic crowns to a one-piece zirconia implant


Statement of problem

The best procedure for cementing a restoration to zirconia implants has not yet been established.


The purpose of this in vitro study was to measure the retention of polymer-infiltrated ceramic crowns to zirconia 1-piece implants using a wide range of cements. The effect of ceramic primer treatment on the retention force was also recorded. The retention results were correlated with the shear bond strength of the cement to zirconia and the indirect tensile strength of the cements to better understand the retention mechanism.

Material and methods

The retention test was performed using 100 polymer-infiltrated ceramic crowns (Vita Enamic) and zirconia implants (ceramic.implant CI) The crowns were cemented with either temporary cement (Harvard Implant semipermanent, Temp Bond), glass-ionomer cement (Ketac Cem), self-adhesive cement (Perma Cem 2.0, RelyX Unicem Automix 2, Panavia SA), or adhesive cement (Multilink Implant, Multilink Automix, Vita Adiva F-Cem, RelyX Ultimate, Panavia F 2.0, Panavia V5 or Panavia 21) (n=5). Additionally ceramic primer was applied on the intaglio crown surface and implant abutment before cementation for all adhesive cements (Multilink Implant, Multilink Automix: Monobond plus; RelyX Ultimate Scotchbond Universal; Vita Adiva F-Cem: Vita Adiva Zr-Prime; Panavia F2.0, Panavia V5: Clearfil Ceramic Primer) and 1 self-adhesive cement containing 10-methacryloyloxydecyl dihydrogen phosphate (MDP) (Panavia SA: Clearfil Ceramic Primer). Crown debond fracture patterns were recorded. Shear bond strength was determined for the respective cement groups to polished zirconia (n=6). The diametral tensile strength of the cements was measured (n=10). Statistical analysis was performed using 1-way or 2-way analysis of variance followed by the Fisher LSD test (α=.05) within each test parameter.


Adhesive and self-adhesive resin cements had shear bond strength values of 0.0 to 5.3 MPa and revealed similar retention forces. Cements containing MDP demonstrated shear bond strength values above 5.3 MPa and displayed increased retention. The highest retention values were recorded for Panavia F 2.0 (318 ±28 N) and Panavia 21 (605 ±82 N). All other adhesive and self-adhesive resin cements attained retention values between 222 ±16 N (Multilink Automix) and 270 ±26 N (Panavia SA), which were significantly higher (P<.05) than glass-ionomer (Ketac Cem: 196 ±34 N) or temporary cement (Harvard Implant semipermanent: 43 ±6 N, Temp Bond: 127 ±13 N). Application of manufacturer-specific ceramic primer increased crown retention significantly only for Panavia SA.


Products containing MDP provided a high chemical bond to zirconia. Self-adhesive and adhesive resin cements with low chemical bonding capabilities to zirconia provided retention force values within a small range (220 to 290 N).

Friday, May 19, 2017

StellaLife Launches First Products

StellaLife®, an innovator in biotechnology products, announced the launch of a new line of products for oral pain management, accelerated healing, and long-term oral healthcare. The patent-pending VEGA® Oral Care system is formulated to improve dental postsurgical recovery and optimize oral systemic health. It is the first line of products launched by StellaLife. 

The VEGA Oral Care system consists of three natural products: a gel, a rinse, and a recovery kit that contains a spray in addition to the gel and rinse. The VEGA products accelerate healing and reduce pain, swelling, and bruising. They also contain anxiolytic properties to help reduce anxiety associated with dental procedures. The spray is for sublingual application, the gel is a topical application, and the rinse is a mouthwash that is antimicrobial and enhances wound healing. 

StellaLife VEGA Oral Care products contain sixteen active ingredients that are part of Homeopathic Pharmacopeia of the United States (HPUS). The products can be used after all dental surgical procedures, including bone and tissue grafting, extractions, implant placements, osseous surgery, biopsies, and dental nonsurgical procedures such as scaling and root planning, and quadrant dentistry. StellaLife products are manufactured in the United States, FDA registered, and follow the GMP guidelines.

“StellaLife’s mission is to improve people’s lives by helping to relieve pain, accelerate healing, and significantly reduce the need for opioids and steroids after dental procedures,” says StellaLife CEO Gennady Sirota. “Our products provide a safe, effective, and natural alternative to help deal with pain, accelerate healing, and promote optimum oral health.”

Dr. William Carter, a periodontist from Tennessee, has been working with the VEGA Oral Care products to heal his patients. Dr. Carter says: “StellaLife's VEGA Oral Care is the best product we have used for post-operative discomfort in the last 13 years.”

Dr. Jason Stoner, a periodontist from Ohio added, “My patients recovered more quickly, reported less pain, and on average required fewer narcotic pain medications when they used StellaLife. We have yet to uncover the limitations of this product.”  

StellaLife® is a biotechnology company that formulates oral health and pain management products that improve dental patients’ experience. VEGA® Oral Care solutions are clinically proven to accelerate healing and reduce pain, bruising and swelling after surgical and non-surgical procedures. In addition, its solutions deliver exceptional long-term oral health care. For more information, please visit or call 800.828.7265.

Thursday, May 18, 2017

Cetylite® Launches New Cool Mint Flavor of Cetacaine® Topical Anesthetic Gel

Pennsauken, NJ (May 15, 2017) — Cetylite® Inc. recently designed a new flavor of one of its flagship products, Cetacaine® Topical Anesthetic Gel. Cetacaine will now feature a Cool Mint flavored gel, which will be available by mid-June. Indicated for anesthesia of accessible mucous membranes (except the eyes), Cetacaine is primarily used to control pain and ease discomfort at the application site.

Cetacaine comes available in three forms; liquid, spray, and gel. The liquid form is applied subgingivally into periodontal pockets, where the viscous drops are easily dispensed using the soft-tipped syringe. The spray form safely dispenses a mist of Cetacaine through the spray cannula to suppress the gag reflex when taking x-rays or impressions. Both the liquid and spray are banana flavored. The gel form, which currently comes in a strawberry flavor, is applied with a cotton swab or micro brush to the site where pain control is needed prior to injection and treatment. Cetacaine Gel reacts with body temperature to melt and absorb quickly into tissue, and distributes evenly and consistently.

“When it comes to products that are used in the operatory, it’s all about trust,” stated Kathy Perini, Marketing Manager of Cetylite. “When a clinician finds a product that they can rely upon and that allows their patients to be comfortable, they recognize the value and become very loyal. We know this because dentists and hygienists tell us their success stories all the time. We are proud to have earned their trust. Cetylite has been able to stand tall all these years by making products that stand the test of time.”

The triple-active formula of Cetacaine (Benzocaine, 14.0%, Butamben 2.0%, and Tetracaine HCL 2.0%) features a rapid onset of less than a minute, and 30-60 minute duration. While many clinicians assume
Cetacaine is comparable to OTC 20% Benzocaine, a blind study published in the peer reviewed publication, Anesthesiology Review, shows the Cetacaine formulation to be more effective than
Benzocaine alone.* Cetacaine Gel offers an outstanding choice for practices looking for an alternative to Benzocaine-only formulations. 

Cetacaine is a prescription topical, for professional use only. It is available through most dental and medical suppliers. For more information about Cetacaine and other Cetylite products and services, please visit

For press inquiries or to schedule an interview with a Cetylite spokesperson, contact Kathy Perini at (856) 665-6111.

*Documentation of these statements available upon request.

About Cetylite Inc.
Founded in 1945 and headquartered Pennsauken, NJ, Cetylite Inc. is a third generation family owned and operated pharmaceutical manufacturer. Cetylite specializes in the manufacturing of topical anesthetics, infection control products, and auxiliary products that are widely used in the wholesale drug, medical, dental, and veterinary fields.

# # #

Wednesday, May 17, 2017

WannaCry Ransomware attacks

As you know, last Friday's WannaCry Ransomware attacks was the largest cyber attack to date.  

In a day it: 
  • Infected over 300,000 computers
  • Over 150 countries were impacted
  • All indications are that the IT gentleman in England saved North America from being hit much worse.
  • Today's reports indicate that the attackers have a new variant that works around what slowed the worm in England

Get a third party assessment of your office data security and the vulnerabilities!

DDS Rescue is providing such an assessment that is sponsored by our dealers so it is no-charge to the doctor. Click the link above to find out more.

Here are a few of the most recent facts regarding the seriousness of the largest threat to data security, that being Ransomware attacks.

From a recent IBM report we learned the following:
  • In 2016 the number of Ransomware attacks increased more than 6,000%.
  • Over 70% of those attacked were forced to pay the ransom due to their backup/recovery system failing them.
From a recent survey of 1,100 Managed Service Providers (IT providers) we learned the following:
  • Of those attacked by Ransomware in 2016, 93% had active anti-virus running.
  • Of those that elected to pay the ransom more then 1 in 4 never recovered their data.
From the McAfee Threats lab report we learned the following:
  • There are more than 9,000,000 separate variants of Ransomware presently active on the internet.
Newer variants of Ransomware are now leaving behind malware called Dridex that seeks out and transmits SS#, DOB and banking credentials to cybercriminals.    

World Summit Tour 2017 — a brand new scientific experience within implant dentistry

San Diego, May 2017—In 2017, Dentsply Sirona Implants welcomed dental professionals from all over the world to the World Summit Tour, the scientific congress on implant dentistry.

The combination of renowned international and regional speakers and a highly multifaceted program arrived in San Diego, the second stop of the four-city tour, following Tokyo, welcoming over 1,000 delegates and 45 speakers and moderators.
“It was an honor to welcome everyone to San Diego for this meeting filled with inspiration, science and learning,” says John Voskuil, VP and General Manager, Dentsply Sirona Implants, North America. “As a company committed to better, safer, faster dental care, this meeting created a tremendous opportunity and environment to truly engage with the dental professionals that we serve. This event featured world-class education and showcased the very latest technology and developments designed to serve the needs of clinicians and laboratory technicians, and advance the field of implant dentistry.”

The theme of the World Summit Tour—Because inspiration and confidence matters—mirrors Dentsply Sirona Implants’ dedication to improved oral health and enhanced quality of life for implant patients worldwide. Each tour stop is designed to inspire clinicians and researchers to share scientific knowledge and clinical experience and discover the latest developments in implant dentistry. By combining general sessions, hands-on workshops, and a choice of various parallel sessions, the program promises to deliver inspiration and education for all members of the treatment team.

The World Summit Tour also included a Poster Competition in the two categories of Clinical Application and Research. Winners were selected by the Scientific Committee members, consisting of Tara Aghaloo, UCLA School of Dentistry; Lyndon Cooper, University of Illinois at Chicago; Barry Goldenberg, private practice St. Louis County; Craig Misch, private practice Sarasota, FL; Georgios Romanos, Stony Brook University, NY, and University of Frankfurt, Germany; and Homa H. Zadeh, University of Southern California.

For more information about the World Summit Tour, registration dates, the venues and the development of the scientific program, please visit

About Dentsply Sirona
Dentsply Sirona is the world’s largest manufacturer of professional dental products and technologies, with a 130-year history of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including dental and oral health products as well as other consumable medical devices under a strong portfolio of world class brands. As The Dental Solutions Company, Dentsply Sirona’s products provide innovative, high-quality and effective solutions to advance patient care and deliver better, safer and faster dentistry.  Dentsply Sirona’s global headquarters is located in York, Pennsylvania, and the international headquarters is based in Salzburg, Austria. The company’s shares are listed in the United States on NASDAQ under the symbol XRAY. Visit for more information about Dentsply Sirona and its products.

This information and any attachment thereto contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance. These forward-looking statements reflect views and assumptions regarding expectations and projections about future events and are based on currently available information or information available on the date of any document incorporated by reference. You can generally identify these forward-looking statements by the use of words such as "may," "could," "estimate," "will," "believe," "anticipate," "think," "intend," "expect," "project," "plan," "target," "forecast", and similar words and expressions. However, these words are not the exclusive means of identifying such statements. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and may include statements relating to future revenues, expenses, margins, profitability, net income/(loss), earnings per share and other measures of results of operations and the prospects of future growth of our business. These forward-looking statements are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict. For a discussion of such risks, uncertainties and other matters that could cause actual results to differ materially, including risks relating to, among other factors, the market for dental products and services, pricing, future sales volume of the Company's products, the possibility of changing economic, market and competitive conditions, dependence on products, dependence on key personnel, technological developments, intense competition, market uncertainties, dependence on distributors, ability to manage growth, dependence on key suppliers, dependence on key members of management, government regulation, our ability to integrate the businesses of Dentsply Sirona, acquisitions and affiliations, readers are urged to carefully review and consider various disclosures made by the Company and Dentsply Sirona in their public filings, including in their Annual Reports on Form 10-K and in their reports on Forms 10-Q and 8-K filed with the Securities and Exchange Commission.
Readers are cautioned not to place undue reliance on such statements, which speak only as of the date hereof. Except as required by law, the Company does not assume any obligation to update any forward-looking statements contained in this document or the attachments to reflect new information or future events or developments after the date any such statement is made.